Aashish Gandhi, MD
Ophthalmology · Urbana, ILNPI 1518989847
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $5,000 of the $6,936 with a category attached, or 72.1%. Alimera Sciences, Inc. accounts for 76.2% of it on its own, with 7 other manufacturers making up the rest. Reporting peaked in 2019 at $6,086 and has fallen 96.3% since, to $225 in 2025.
Across 43 payments — averaging $161.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alimera Sciences, Inc.$5K
- Regeneron Healthcare Solutions, Inc.$852
- Novartis$322
- AbbVie$235
- Genentech USA, Inc.$101
- Astellas Pharma US Inc$67
- plus $72 from 2 others
What the payments were for
- Speaking & faculty fees$5,00072%
- Food & beverage$1,91628%
- Gifts$190%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alimera Sciences, Inc. | 6 | $5,286 |
| Regeneron Healthcare Solutions, Inc. | 11 | $852 |
| Novartis | 6 | $322 |
| AbbVie(2 entities) | 9 | $235 |
| Genentech USA, Inc. | 5 | $101 |
| Astellas Pharma US Inc | 4 | $67 |
| Amgen | 1 | $53 |
| Carl Zeiss Meditec AG | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,936 in reported general payments places this provider in the 80th percentile of 773 ophthalmology providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 118 | $5,834 |
| Brimonidine Tartrate | 157 | $2,180 |
| Ketorolac Tromethamine | 84 | $1,329 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 65 | $898 |
| Latanoprost | 118 | $827 |
| Dorzolamide Hcl | 50 | $752 |
| Timolol Maleate | 49 | $601 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 19 | $220 |
| ErythromycinErythromycin Base | 12 | $120 |
Paid to pharmacies, not to this prescriber.
Other ophthalmology in Urbana
- Leanne LabriolaUrbana$43K
- Seenu HariprasadChicago$2.3M
- Lisa NijmSpringfield$1.7M
- Kathleen MornoNorth Riverside$1.2M
- Veeral ShethOak Forest$716K
- James KatzDes Plaines$642K
- Mitchell JacksonLake Villa$584K
- David LubeckHomewood$575K
- Parag MajmudarHighland Park$451K
- Daniel OwensLombard$343K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.